Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Keytruda + cinrebafusp alfa
- Development stage
- Discontinued
- Lead developer
- Pieris Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Keytruda (pembrolizumab) in combination with cinrebafusp alfa (PRS-343) is an investigational immunotherapy regimen developed for HER2-positive advanced solid tumors. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Cinrebafusp alfa is a first-in-class bispecific Anticalin-antibody fusion protein designed to target HER2 and provide localized 4-1BB (CD137) agonism. By binding to HER2-expressing tumor cells, cinrebafusp alfa clusters 4-1BB on tumor-infiltrating lymphocytes, leading to targeted T-cell activation. The combination therapy was evaluated in Phase 1 trials to determine if the synergy between checkpoint inhibition and localized costimulation could improve outcomes in patients with HER2-positive breast, gastric, and bladder cancers.
- Brand names
- Keytruda
- Other names
- pembrolizumabcinrebafusp alfa
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TNFRSF9 (CD137 extracellular domain)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Keytruda + cinrebafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keytruda + cinrebafusp alfa.